Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Comparing p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil (5-FU)44.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“On the other hand, the same report showed that p53-deficient cells displayed a higher sensitivity towards topoisomerase inhibitors such as Adriamycin.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 4×
“We attribute this difference to the small amount of p53independent p21 induction following DNA damage that occurs after adriamycin treatment of p53-deficient cells (not shown), similar to that observed after γ-irradiation (14).”
BackgroundMethodInfluentialSelf-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“Introduction The p53 gene is inactivated in the majority of human cancers, resulting in profound effects on cell birth and death processes (1, 2).”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469 · cited 1×
“with mouse cells, for example, have provided unequivocal evidence of drug resistance after p53 inactivation (9, 10), but the extrapolation of these results to humans is far from straightforward.”
BackgroundApoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · cited 1×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Research works printed but not linked: 6
- Hawkins, 1996, Cancer Res, 56, 892
- O’Connor, 1997, Cancer Res, 57, 4285
- Waldman, 1995, Cancer Res, 55, 5187
- Geoffroy, 1994, Oncol Res, 6, 581
- Wyllie, 1997, Eur J Cell Biol, 73, 189
- Cory, 1979, Cancer Res, 39, 4905
Cited by
Items 301–400 of 1,000
Staples, C. J., Owens, D. M., Maier, J. V., Cato, A. C. B., & Keyse, S. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.117911 · Cited by 79
Giovannetti, E., Backus, H. H. J., Wouters, D., Ferreira, C. G., van Houten, V. M. M., Brakenhoff, R. H., Poupon, M. F., Azzarello, A., Pinedo, H. M., & Peters, G. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603639 · Cited by 79
“Mutations in p53 have been related with resistance to chemotherapy (Lowe et al, 1993) and CRC cells with p53 mutated or disrupted through homologous recombination were less sensitive to 5-FU (O’Connor et al, 1997; Bunz et al, 1999).”
BackgroundGewirtz, D. A. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006414422919 · Cited by 85
“have shown that adriamycin induces apoptosis in p53 and p21 knockouts and not in p53 wild-type cells [82]; interestingly, however, while the apoptotic potential was clearly different, there was no evident difference in the response to ionizing radiation in the p53 wild type and p53 mutated tumor cell xenografts [82].”
Tumor senescence as a determinant of drug response in vivo
Roninson, I. B. (2002) · Drug Resistance Updates · doi:10.1016/s1368764602001103 · Cited by 83
“For example, p53 knockout in HCT116 carcinoma makes these cells more resistant to 5-fluorouracyl but at the same time sensitizes them to doxorubicin and ionizing radiation (Bunz et al., 1999).”
BackgroundJakob, C., Liersch, T., Meyer, W., Becker, H., Baretton, G. B., & Aust, D. E. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1060 · Cited by 78
Di, X. M., Shiu, R. P. C., Newsham, I., & Gewirtz, D. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.12.016 · Cited by 84
Chaudhry, G.-E.-S., Akim, A. M., Sung, Y. Y., & Muhammad, T. S. T. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2553-8_16 · Cited by 88
Predictive value of CHFR and MLH1 methylation in human gastric cancer
Li, Y., Yang, Y., Lu, Y., Herman, J. G., Brock, M. V., Zhao, P., & Guo, M. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0370-2 · Cited by 80
“Cell-cycle checkpoint dysfunction is often associated with sensitivity of chemotherapeutic agents [14, 15], but mutation of mitotic checkpoint genes is rare in gastric cancer [16, 17].”
BackgroundKoornstra, J. J., de Jong, S., Hollema, H., de Vries, E. G. E., & KLEIBEUKER, J. H. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00228-1 · Cited by 84
“It has also been found that p53 has profound effects on responses to chemotherapeutic drugs used in colorectal cancer, and that these effects vary considerably depending on the drug [126].”
BackgroundMitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers
Kumar, R., Coronel, L., Somalanka, B., Raju, A., Aning, O. A., An, Ö., Ho, Y. S., Chen, S., Mak, S. Y., Hor, P. Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05805-1 · Cited by 81
miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2
Jansson, M., Damas, N. D., Lees, M. J., Jacobsen, A., & Lund, A. H. (2014) · Oncogene · doi:10.1038/onc.2014.130 · Cited by 81
del Muro, X. G., Condom, E., Vigués, F., Castellsagué, X., Figueras, A., Muñoz, J., Solà, J., Soler, T., Capellá, G., & Germà, J. R. (2004) · Cancer · doi:10.1002/cncr.20200 · Cited by 80
Prohibitin 1 Modulates Mitochondrial Stress-Related Autophagy in Human Colonic Epithelial Cells
Kathiria, A. S., Butcher, L. D., Feagins, L. A., Souza, R. F., Boland, C. R., & Theiss, A. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031231 · Cited by 78
“HCT116 cells, including p53 null cells [51], also showed the conversion of LC3-I to LC3-II and increased beclin-1 protein expression suggesting that the effect of TNFa and IFNc to increase autophagy and decrease PHB protein expression is independent of p53 signaling (Figure 1C and 1D).”
Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention
Lissa, D., Senovilla, L., Rello-Varona, S., Vitale, I., Michaud, M., Pietrocola, F., Boilève, A., Obrist, F., Bordenave, C., Garcia, P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318440111 · Cited by 72
“The microtubule inhibitor nocodazole and the actin cytoskeleton inhibitor cytochalasin D increased the frequency of tetraploid p53 HCT116 cells (33), and similarly depletion of Aurora kinase B (AURKB) induced tetraploidization (DNA content >4n) of WT HCT116 cells.”
BackgroundBunz, F. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00059-5 · Cited by 81
Self-citationSpierings, D. C. J., de Vries, E. G. E., Vellenga, E., & de Jong, S. (2003) · The Journal of Pathology · doi:10.1002/path.1373 · Cited by 72
“Disruption of the p21 gene by homologous recombination can cause cells that would otherwise undergo p53-dependent cell cycle arrest to undergo apoptosis instead [55,56].”
Oncogenes and tumor angiogenesis
Rak, J. W., & Yu, J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.014 · Cited by 90
p21WAF1/CIP1 and cancer: A shifting paradigm?
Gartel, A. L. (2009) · BioFactors · doi:10.1002/biof.26 · Cited by 71
“p21 usually plays inhibitory role in apoptosis [8,41,42], but in some cases [43–45] it induces cell death [8,10].”
BackgroundNottrott, S., Schoentaube, J., Genth, H., Just, I., & Gerhard, R. (2007) · APOPTOSIS · doi:10.1007/s10495-007-0074-8 · Cited by 73
“In addition to the HCT 116 p53 cell line a p53 cell line was generated by homologous recombination to investigate the impact of p53 on cell survival after treatment DNAdamaging agents [31].”
MethodYu, J., & Tiwari, S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.6.573 · Cited by 76
A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage
Meyers, M., Hwang, A., Wagner, M. W., Bruening, A. J., Veigl, M. L., Sedwick, W. D., & Boothman, D. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206941 · Cited by 76
“However, contradictory results have been reported by other groups (Bunz et al., 1999; Vikhanskaya et al., 1999).”
ResultRegulation of p53 by TopBP1: a Potential Mechanism for p53 Inactivation in Cancer
Liu, K., Bellam, N., Lin, H., Wang, B., Stockard, C. R., Grizzle, W. E., & Lin, W.-C. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01140-08 · Cited by 81
“It is worth noting that deletion of p53 or p21 in HCT116 cells leads to a decrease of G1 fraction and an increase of G2/M fraction after adriamycin treatment (4, 48).”
BackgroundRegulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer
Kumar, A., Singh, A. K., Singh, H., Thareja, S., & Kumar, P. (2022) · Medical Oncology · doi:10.1007/s12032-022-01864-z · Cited by 76
Myc Is Required for Activation of the ATM-Dependent Checkpoints in Response to DNA Damage
Guerra, L., Albihn, A., Tronnersjö, S., Yan, Q., Guidi, R., Stenerlöw, B., Sterzenbach, T., Josenhans, C., Fox, J. G., Schauer, D. B., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008924 · Cited by 76
“While the HCT116 cells readily respond to genotoxic stress with normal induction of p53 [29] and as confirmed here, the TGR-1 cells exhibited delayed p53 stabilization, suggesting that the latter may have an altered p53 response.”
BackgroundMethodMechanistic understanding of β-cryptoxanthin and lycopene in cancer prevention in animal models
Lim, J. Y., & Wang, X. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158652 · Cited by 76
“Many cancers exhibit loss of p53, which contributes to chemotherapy resistance [147]; thus, re-activation of p53 is a potent strategy for treating cancer.”
BackgroundLiu, Y., Azizian, N. G., Sullivan, D. K., & Li, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-34890-6 · Cited by 79
OʼDonnell, R. T., DeNardo, S. J., Miers, L. A., Lamborn, K. R., Kukis, D. L., DeNardo, G. L., & Meyers, F. J. (2001) · The Prostate · doi:10.1002/pros.10029 · Cited by 68
“However, DNA of p53 de®cient cells can still be damaged by ionizing radiation and nuclear changes consistent with apoptosis result [38].”
BackgroundAdvances in Pharmacogenetics and Pharmacogenomics
Vesell, E. S. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022009666 · Cited by 68
“Mutations of p53 in these cells would suggest that DNA-damaging drugs such as doxorubicin be selected as antitumor agents, rather than drugs such as 5-FU that act posttranscriptionally by perturbing RNA.(31) The second example involves infectious diseases and the association of specific genetic loci with altered susce…”
BackgroundInfluentialRavi, R. K., Jain, A. J., Schulick, R. D., Pham, V., Prouser, T. S., Allen, H. E., Mayer, E.-G., Yu, H., Pardoll, D. M., Ashkenazi, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2488 · Cited by 77
“derivatives of HCT116 cells were generated by disruption of p53 alleles by gene targeting (13).”
BackgroundMethodInfluentialATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
Sullivan, K. D., Padilla-Just, N., Henry, R. E., Porter, C. C., Kim, J., Tentler, J. J., Eckhardt, S. G., Tan, A. C., DeGregori, J., & Espinosa, J. M. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.965 · Cited by 67
“…of HCT116 cells with Nutlin-3 and the ATM-specific inhibitor KU-55933 26 (hereafter referred to as ATMi) results in activation of executioner caspase 3 and apoptotic cell death comparable to that seen with the chemotherapeutic agent 5FU, a strong elicitor of p53-dependent cell death 19 (Fig.”
PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells
Sun, Q., Ming, L., Thomas, S. M., Wang, Y., Chen, Z. G., Ferris, R. L., Grandis, J. R., Zhang, L., & Yu, J. (2009) · Oncogene · doi:10.1038/onc.2009.108 · Cited by 69
“The p53 knockout HCT 116 colon cancer cells have been described (Bunz et al., 1999).”
BackgroundActivation of the ribosomal protein L13 gene in human gastrointestinal cancer
Kobayashi, T., Sasaki, Y., Oshima, Y., Yamamoto, H., Mita, H., Suzuki, H., Toyota, M., Tokino, T., Itoh, F., Imai, K., et al. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.18.1.161 · Cited by 66
Hayward, R. L., Macpherson, J. S., Cummings, J., Monia, B. P., Smyth, J. F., & Jodrell, D. I. (2003) · PubMed · Cited by 82
Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome
McGowan, K. A., Pang, W. W., Bhardwaj, R., Perez, M. G., Pluvinage, J. V., Glader, B. E., Malek, R., Mendrysa, S. M., Weissman, I. L., Park, C. Y., et al. (2011) · Blood · doi:10.1182/blood-2010-11-318584 · Cited by 63
Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Yee-Lin, V., Pooi-Fong, W., & Soo-Beng, A. K. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557517666170717125821 · Cited by 65
“Mutations in p53 alter its ability for DNA repair, thus contributing to cancer development [106-108].”
BackgroundChemistry of Fluorinated Pyrimidines in the Era of Personalized Medicine
Gmeiner, W. H. (2020) · Molecules · doi:10.3390/molecules25153438 · Cited by 66
“This approach shows promise for the treatment of malignancies with mutational profiles that limit the efficacy of conventional FPs, such as p53 mutations [63], and so may be important for a personalized medicine approach to treatment since many anti-cancer drugs, including 5-FU, are relatively less effective towards p…”
BackgroundExpression of CtBP family protein isoforms in breast cancer and their role in chemoresistance
Birts, C. N., Harding, R., Soosaipillai, G., Halder, T., Azim-Araghi, A., Darley, M., Cutress, R., Bateman, A. C., & Blaydes, J. P. (2010) · Biology of the Cell · doi:10.1042/bc20100067 · Cited by 67
“The mechanistic basis of this is currently unclear, although it is of interest that, compared with other genotoxic agents, the antiproliferative affects of 5-fluorouracil can be shown to be highly dependent on the presence of a functional p53 response pathway (Bunz et al., 1999).”
Backgroundp53 promotes repair of heterochromatin DNA by regulating JMJD2b and SUV39H1 expression
Zheng, H., Chen, L., Pledger, W. J., Fang, J., & Chen, J. (2014) · Oncogene · doi:10.1038/onc.2013.6 · Cited by 66
“Previous study showed that p53 knockout in HCT116 reduces cell survival after IR (28).”
BackgroundPopat, S., Chen, Z., Zhao, D., Pan, H., Hearle, N., Chandler, I. R., Shao, Y., Aherne, W., & Houlston, R. S. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl301 · Cited by 69
“Several in vitro studies have reported a relationship between TP53 mutation status and sensitivity to a number of cytotoxic agents, including fluoropyrimidines [25–27].”
BackgroundATR mediates cisplatin resistance in a p53 genotype-specific manner
Sangster-Guity, N., Conrad, B. H., Papadopoulos, N., & Bunz, F. (2011) · Oncogene · doi:10.1038/onc.2010.624 · Cited by 65
Self-citationYan, W., Liu, G., Scoumanne, A., & Chen, X. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0810 · Cited by 64
Cell cycle perturbation and acquired 5-fluorouracil chemoresistance.
Guo, X., Goessl, E., Jin, G., Collie-Duguid, E. S. R., Cassidy, J., Wang, W., & O’Brien, V. (2008) · PubMed · Cited by 65
Wang, C., van Rijnsoever, M., Grieu, F., Bydder, S. A., Elsaleh, H., Joseph, D. J., Harvey, J. M., & Iacopetta, B. J. (2003) · Oncology · doi:10.1159/000069311 · Cited by 73
“Regardless of its prognostic value, both preclinical [”
Backgroundp21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation
Xia, M., Knezevic, D., & Vassilev, L. T. (2011) · Oncogene · doi:10.1038/onc.2010.413 · Cited by 64
“HCT116 human colon carcinoma cells have been shown to undergo cellcycle arrest following DNA damage in the presence of doxorubicin, but their p21-null variant undergoes apoptosis (Bunz et al., 1999; Chan et al., 2000).”
BackgroundMethodInfluentialAgostini, M., Zangrando, A., Pastrello, C., D’Angelo, E., Romano, G., Giovannoni, R., Giordan, M., Maretto, I., Bedin, C., Zanon, C., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1046652 · Cited by 72
“To further investigate the role of XRCC3 gene in the chemoresistance in colon carcinoma, a siRNA-mediated knockdown of this gene was performed in a well-known in vitro model of 5-FU chemoresistance of colon carcinoma, the HCT116 p53¡/¡ cell line.(15) The down-regulation of XRCC3 in these cells re-sensitized the chemor…”
BackgroundMethodZhang, Y., Gao, Y., Zhang, G., Huang, S., Dong, Z., Kong, C., Su, D., Du, J., Zhu, S., Liang, Q., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25365 · Cited by 64
“Dox induces apoptosis by p53-dependent and p53-independent mechanisms, and p53-dependent and p53-independent expression of p21 protects cells from Doxinduced apoptosis.(10) In human prostate and colorectal cancer cells with wild-type p53, Dox strongly induced p53 expression, while p21 expression was increased at senes…”
BackgroundSelf-citationCasein kinase 1α–dependent feedback loop controls autophagy in RAS-driven cancers
Cheong, J. K., Zhang, F., Chua, P. J., Bay, B. H., Thorburn, A., & Virshup, D. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78018 · Cited by 64
Torres, Y. R., Bugni, T. S., Berlinck, R. G. S., Ireland, C. M., Magalhães, A., Ferreira, A. G., & da Rocha, R. M. (2002) · The Journal of Organic Chemistry · doi:10.1021/jo011174h · Cited by 64
SirT1 fails to affect p53‐mediated biological functions
Kamel, C., Abrol, M., Jardine, K., He, X., & McBurney, M. W. (2006) · Aging Cell · doi:10.1111/j.1474-9726.2006.00191.x · Cited by 64
“The HCT116 human colorectal carcinoma cell line and its p53-null derivative (Brattain et al., 1981; Bunz et al., 1999) were used as controls to verify that the expression from the p21 promoter was dependent on endogenous p53.”
MethodDoes p53 status influence tumor response to anticancer therapies?
Pirollo, K. F., Bouker, K. B., & Chang, E. H. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200007000-00002 · Cited by 64
“Interestingly, Bunz et al.25 demonstrated that targeted deletion of p53 in colorectal cancer cell lines resulted in resistance to 5-FU both in vitro and in an in vivo xenograft model.”
BackgroundWilliams, J. R., Zhang, Y., Zhou, H., Gridley, D. S., Koch, C. J., Russell, J., Slater, J. S., & Little, J. B. (2008) · International Journal of Radiation Biology · doi:10.1080/09553000801953342 · Cited by 62
“There are multiple reviews of the relationship between radiosensitivity of cells and their p53 status (Bristow et al. 1996, Dahm-Daphi 2000, Matsui et al. 2001, Weber & Wenz 2002). In general, these reports show an association between cellular radiosensitivity and TP53 status or p53 protein levels, cells that express…”
InfluentialSelf-citationWendt, J., von Haefen, C., Hemmati, P., Belka, C., Dörken, B., & Daniel, P. T. (2005) · Oncogene · doi:10.1038/sj.onc.1208580 · Cited by 64
“There, disruption of p53 or p21CIP/WAF 1 abrogates cell cycle checkpoint control upon IR and results in a drastically enhanced sensitivity to IR-induced apoptosis (Waldman et al., 1996; Bunz et al., 1999).”
BackgroundmRTVP-1, a Novel p53 Target Gene with Proapoptotic Activities
Ren, C., Li, L., Goltsov, A. A., Timme, T. L., Tahir, S. A., Wang, J., Garza, L., Chinault, A. C., & Thompson, T. C. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3345-3357.2002 · Cited by 62
“The human colon cancer cell lines HCT116 p53 / , HCT116 p53 / (4) were grown in McCoy’s 5A with 10% FBS.”
MethodAgarwal, S., Afaq, F., Bajpai, P., Kim, H., Elkholy, A., Behring, M. P., Chandrashekar, D. S., Diffalha, S. A., Khushman, M. M., Sugandha, S. P., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13201 · Cited by 61
Proteasome Inhibitors Induce p53-Independent Apoptosis in Human Cancer Cells
Pandit, B., & Gartel, A. L. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.010 · Cited by 62
Toffoli, G., Biason, P., Russo, A. G., Mattia, E. D., Cecchin, E., Hattinger, C. M., Pasello, M., Alberghini, M., Ferrari, C., Scotlandi, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2249 · Cited by 69
Negative Regulation of p53 Functions by Daxx and the Involvement of MDM2
Zhao, L., Liu, J., Sidhu, G. S., Niu, Y., Liu, Y., Wang, R., & Liao, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406743200 · Cited by 63
Bidard, F., Matthieu, M.-C., Chollet, P. J. M., Raoefils, I., Abrial, C., Dômont, J., Spielmann, M., Delaloge, S., André, F., & Penault-Llorca, F. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn039 · Cited by 63
“DNA-damaging drugs function in a p53-dependent manner and p53 disruption makes numerous human cancer cells more sensitive to apoptosis induced by adriamycin in vitro [7, 8].”
BackgroundNieto, Y. L., Cagnoni, P. J., Nawaz, S., Shpall, E. J., Yerushalmi, R., Cook, B., Russell, P., McDermitt, J., Murphy, J. R., Bearman, S. I., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2070 · Cited by 68
Glucose-induced CRL4COP1-p53 axis amplifies glycometabolism to drive tumorigenesis
Su, Y., Luo, Y., Zhang, P., Lin, H., Pu, W., Zhang, H., Wang, H., Hao, Y., Xiao, Y., Zhang, X., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.06.010 · Cited by 66
Adamsen, B. L., Kravik, K., Clausen, O. P. F., & Angelis, P. D. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.6.1491 · Cited by 64
Ribosomal Protein S27-like, a p53-Inducible Modulator of Cell Fate in Response to Genotoxic Stress
Li, J., Tan, J. Y., Li, Z., Banerjee, B., Yang, X., Chau, J. F. L., Lee, P. L., Hande, M. P., Li, B., & Yu, Q. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1088 · Cited by 64
Hsp90 Inhibitors Promote p53-Dependent Apoptosis through PUMA and Bax
He, K., Zheng, X., Zhang, L., & Yu, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0284 · Cited by 65
“Isogenic HCT 116 knockout cell lines including p53-KO (26), PUMA-KO (27), BAX-KO (28), p21-KO (29), p21/PUMA double KO (DKO; ref.”
Rigouts, L., Miotto, P., Schats, M., Lempens, P., Cabibbe, A. M., Galbiati, S., Lampasona, V., de Rijk, P., Cirillo, D. M., & de Jong, B. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-48289-9 · Cited by 60
Roles of Apoptosis and Cellular Senescence in Cancer and Aging
Cerella, C., Grandjenette, C., Dicato, M. A., & Diederich, M. F. (2016) · Current Drug Targets · doi:10.2174/1389450116666150202155915 · Cited by 71
Koivusalo, R., Krausz, E., Ruotsalainen, P., Helenius, H. Y. M., & Hietanen, S. (2002) · PubMed · Cited by 60
Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways
Blaydes, J. P., Craig, A. L., Wallace, M., Ball, H. M.-L., Traynor, N. J., Gibbs, N. K., & Hupp, T. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203773 · Cited by 66
“Amongst the most clearly de®ned of these stimuli are the cellular changes associated with malignant transformation and immortalization (Bond et al., 1996), as well as responses to the genotoxic damage induced by the majority of currently available anticancer modalities (Bunz et al., 1999).”
BackgroundPotent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin‐3 in gastric cancer cells
Endo, S., Yamato, K., Hirai, S., Moriwaki, T., Fukuda, K., Suzuki, H., Abei, M., Nakagawa, I., & Hyodo, I. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01821.x · Cited by 66
p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells
Toscano, F., Parmentier, B., Fajoui, Z. E., Estornes, Y., Chayvialle, J., Saurin, J., & Abello, J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.05.001 · Cited by 72
“A role of p53 mutations in resistance to chemotherapeutic agents is not a surprise, and has been demonstrated in several cell line models [3,9,10,28], including the resistance to 5-FU-induced apoptosis of p53-null colorectal cancer cells [5].”
BackgroundKathiria, A. S., Neumann, W. L., Rhees, J., Hotchkiss, E. C., Cheng, Y., Genta, R. M., Meltzer, S. J., Souza, R. F., & Theiss, A. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0603 · Cited by 59
“g-Irradiation g-Irradiation was used to induce DNA damage in WT and p53 / HCT116 cells (27) after 72 hours of transfection with pEGFPN1 vector or pEGFPN1-PHB.”
MethodGarcía, M. Á., Carrasco, E., Aguilera, J., Alvarez, P. J., Rivas, C., Rosa, J. M. C., Prados, J. C., Calleja, M. Á., Estéban, M., Marchal, J. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023887 · Cited by 70
“Cell culture and reagents PKR and PKR MEFs [32], and human colon HCT116 p53 and p53 cells [7], were kindly provided by M Esteban (National Center of Biotechnology, Spain) and B.”
BackgroundMethodPrabhu, V. V., Hong, B., Allen, J. E., Zhang, S., Lulla, A. R., Dicker, D. T., & El‐Deiry, W. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-2430 · Cited by 60
“Loss of p53 function via mutation or allelic loss also contributes to resistance to chemotherapy [2, 4].”
BackgroundGosslau, A., Pabbaraja, S., Knapp, S., & Chen, K. Y. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.027 · Cited by 64
“To directly test this possibility, we investigated the biological effects of MC-4 and MR-4 in a set of three isogenetic HCT116 cell lines inwhich the p53 gene or the p21 genewas disruptedthrough homologous recombination: p53/p21-wild type, p53�/�, and p21�/� ( Bunz et al.,1999 ).”
MethodBar, J., Lukaschuk, N., Zalcenstein, A., Wilder, S., Seger, R., & Oren, M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401677 · Cited by 63
“key mediator of p53-dependent growth inhibition and a welldocumented attenuator of apoptosis, failed to protect HCT116 cells from 5FU-induced death.(48) Furthermore, LY294002”
BackgroundHan, J., Goldstein, L. A., Hou, W., Gastman, B., & Rabinowich, H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081042 · Cited by 67
A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer
Watanabe, Y., Koi, M., Hemmi, H., Hoshai, H., & Noda, K. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2037 · Cited by 59
“…Leith et al, 1999), the expression of glutathione-associated enzymes (Nishimura et al, 1996; D’Incalci et al, 1998), and the loss of p53 function (Bunz et al, 1999; Zheng et al, 1999), there is no clear understanding about the mechanism of the resistance to CDDP acquired during chemotherapy for…”
BackgroundPrognostic and predictive molecular markers in colorectal carcinoma.
Bendardaf, R., Lamlum, H., & Pyrhönen, S. O. (2004) · PubMed · Cited by 71
Liu, J.-D., Wang, Y., Chen, C.-H., Yu, C.-F., Chen, L.-C., Lin, J.-K., Liang, Y., Lin, S.-Y., & Ho, Y. (2003) · Molecular Carcinogenesis · doi:10.1002/mc.10118 · Cited by 59
“As described previously [59,60,65], p21/Cip1 induction”
BackgroundNagayama, Y., Yokoi, H., Takeda, K., Hasegawa, M., Nishihara, E., Namba, H., Yamashita, S., & Niwa, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.11.4081 · Cited by 65
Conventional chemotherapy: millions of cures, unresolved therapeutic index
Letai, A. G., & de Thé, H. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00778-4 · Cited by 121
“These studies suggested that, upon chemotherapy, TP53 primarily drives cell cycle arrest and/or senescence, allowing subsequent DNA repair 71 in both normal cells and tumour cells.”
Schwartz, G. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.18.341 · Cited by 59
Uramoto, H., Izumi, H., Nagatani, G., Ohmori, H., Nagasue, N., Ise, T., Yoshida, T., Yasumoto, K., & Kohno, K. (2003) · Biochemical Journal · doi:10.1042/bj20021646 · Cited by 58
Wilsker, D., & Bunz, F. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0679 · Cited by 57
Self-citationThe mutant p53 mouse as a pre-clinical model
Jackson, J. G., & Lozano, G. (2013) · Oncogene · doi:10.1038/onc.2012.610 · Cited by 57
Phelps, M., Phillips, A., Darley, M., & Blaydes, J. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412334200 · Cited by 57
Role of DNA mismatch repair in apoptotic responses to therapeutic agents
Meyers, M., Hwang, A., Wagner, M. W., & Boothman, D. A. (2004) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20056 · Cited by 66
“One group [Bunz et al., 1999] reported that 5-FU treatment resulted in significant apoptosis in HCT116 cells when 258 Meyers et al.”
Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
Motwani, M., Sirotnak, F. M., She, Y., Commes, T., & Schwartz, G. K. (2002) · PubMed · Cited by 57
Hearnes, J. M., Mays, D. J., Schavolt, K. L., Tang, L., Jiang, X., & Pietenpol, J. A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10148-10158.2005 · Cited by 57
“3, we performed Q-RT-PCR analysis on RNA isolated from three cell model systems: (i) the isogenic pair of HCT116 p53 / and p53 / cells (6) treated with ADR, (ii) an inducible H1299 cell line in which p53 expression was under the control of the ecdysone promoter and induced by ponasterone A addition (HIp53), and (iii)…”
MethodVikhanskaya, F., Marchini, S., Marabese, M., Galliera, E., & Broggini, M. (2001) · PubMed · Cited by 57
Pharmacogenetic determinants of anti-cancer drug activity and toxicity
Danesi, R., de Braud, F., Fogli, S., Paolo, A. D., & Tacca, M. D. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01742-9 · Cited by 57
Smith, C. S., Golubovskaya, V., Peck, E., Xu, L., Monia, B. P., Yang, X., & Cance, W. G. (2005) · Melanoma Research · doi:10.1097/00008390-200510000-00003 · Cited by 57
Luciani, M. G., Campregher, C., & Gasché, C. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm101 · Cited by 58
“The p53-null HCT116p53� /� is a cell line isogenetic to the wild-type clone HCT116 created by targeted homologous recombination [Figure S1 and ( 28 )].”
MethodPathak, S., Meng, W., Nandy, S. K., Ping, J., Bişgin, A., Helmfors, L., Waldmann, P., & Sun, X.-F. (2015) · Oncotarget · doi:10.18632/oncotarget.5815 · Cited by 59
“com/oncotarget sensitive to radiation and adriamycin but less sensitive to 5-fluorouracil [17].”
Pereira, D. M., Simões, A. E. S., Gomes, S. E., Castro, R. E., Carvalho, T., Rodrigues, C. M. P., & Borralho, P. M. (2016) · Oncotarget · doi:10.18632/oncotarget.9107 · Cited by 58
“The antitumor activity of 5-FU has been greatly attributed to its ability to induce both p53 accumulation and activity [17, 18], leading to the direct transcription of cell-cycle inhibitory genes, such as p21/WAF1, and to the upregulation of several pro-apoptotic targets, including PUMA [18, 30].”
BackgroundHan, J., Li, J., Tang, K., Zhang, H., Guo, B., Hou, N., & Huang, C. Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.023 · Cited by 56
Longley, D. B., Allen, W. L., McDermott, U., Wilson, T. R., Latif, T., Boyer, J. D., Lynch, M., & Johnston, P. G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0532 · Cited by 57
“Several preclinical studies have demonstrated that loss of p53 function reduces cellular sensitivity to 5-FU (6, 21).”
BackgroundThe unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer
Thornton, M., Aslam, M. A., Tweedle, E. M., Ang, C. W., Campbell, F., Jackson, R., Costello, E., Rooney, P. S., Vlatković, N., & Boyd, M. T. (2013) · International Journal of Cancer · doi:10.1002/ijc.28137 · Cited by 57
“The tumor suppressor p53 is frequently mutated in CRC,(31) and is a key regulator of apoptosis with a welldocumented role in apoptotic signalling in response to 5FU.(32) Moreover, on-going clinical trials in other cancers suggest that p53 can provide a useful biomarker for patient stratification (NCRI trial CLL-206).”
BackgroundCell Death Pathways in Response to Antitumor Therapy
Portugal, J., Bataller, M., & Mansilla, S. (2009) · Tumori Journal · doi:10.1177/030089160909500401 · Cited by 67
Anticancer metallohelices: nanomolar potency and high selectivity
Kaner, R. A., Allison, S. J., Faulkner, A. D., Phillips, R. M., Roper, D. I., Shepherd, S. L., Simpson, D. H., Waterfield, N. R., & Scott, P. (2015) · Chemical Science · doi:10.1039/c5sc03677a · Cited by 60
Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma
Igbinigie, E., Guo, F., Jiang, S., Kelley, C., & Li, J. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.11.023 · Cited by 67
Metadata
- Authors
- Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Georgetown University (US)
- Johns Hopkins University (US)
- Corresponding author
- Vogelstein, Bert
- Venue
- Journal of Clinical Investigation
- Published
- 1999-08-01
- Volume
- 104
- Issue
- 3
- Pages
- 263-269
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC408422
- OpenAlex
- W1982097971
- Cited by
- 1,044
- References
- 33
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
- MeSH terms
- Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.